Biologic therapeutics biotech
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Paul Tudor Jones / Tudor | 61 | New buy | 8,542 | $854,883 | 0.0% |
| Steve Cohen / Point72 | 75 | Trimmed -36% | 16,673 | $1,668,634 | 0.0% |
| Filed | Insider | Role | Shares | Value | |
|---|---|---|---|---|---|
| 2026-10-14 | Lappe Mark | director+officer | 10,040 | $848,977 | Form 4 |
| 2026-09-28 | Lappe Mark | director+officer | 10,000 | $998,784 | Form 4 |
| 2026-09-23 | Kayyem Jon Faiz | director | 5,000 | $500,000 | Form 4 |
| 2026-09-17 | Kayyem Jon Faiz | director | 5,000 | $500,000 | Form 4 |
| 2026-09-08 | FORSYTH DOUGLAS (cluster of 3) | director | 2,500 | $286,617 | Form 4 |
| 2026-09-08 | Kayyem Jon Faiz (cluster of 3) | director | 5,000 | $567,580 | Form 4 |
| 2026-09-08 | Lappe Mark (cluster of 3) | director+officer | 25,000 | $2,645,399 | Form 4 |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.